07:00 , Oct 29, 2015 |  BC Innovations  |  Product R&D

Qureing antibiotic resistance

QureTech Bio AB is targeting chlamydia and tuberculosis with compounds that disable, rather than kill, pathogens to circumvent antibiotic resistance. By targeting the organisms' virulence factors, the company hopes to spare the host flora and...
02:08 , Aug 14, 2015 |  BC Extra  |  Top Story

Roche acquiring GeneWeave

Roche (SIX:ROG; OTCQX:RHHBY) will acquire diagnostic play GeneWeave Biosciences Inc. (Los Gatos, Calif.) for $190 million up front and up to $235 million in milestones. Roche will gain GeneWeave's vivoDx platform, which is in development...
07:00 , Jun 15, 2015 |  BioCentury  |  Finance

Spero's Finnish-ing touch

While Spero Therapeutics LLC found its first antibiotic asset in its backyard, the biotech looked overseas for its newest program. The result is a deal for a portfolio of antibiotic potentiators plus a $30 million...
02:10 , Jun 9, 2015 |  BC Extra  |  Financial News

Spero raises $30M, expands antibiotic portfolio

Spero Therapeutics LLC (Cambridge, Mass.) raised $30 million in a tranched series A round led by new investor Lundbeckfond Ventures. Additional new investors Merck Research Ventures and the Kraft Group joined existing investors Atlas Venture,...
02:24 , Feb 5, 2015 |  BC Extra  |  Company News

The Medicines Co. acquires Annovation

The Medicines Co. (NASDAQ:MDCO) exercised its option to acquire Annovation Biopharma Inc. (Cambridge, Mass.) for $28.4 million in cash up front. Annovation shareholders are eligible for up to $26.3 million in clinical and regulatory milestones,...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Atlas' next chapter

After separating from the tech group, Atlas Venture 's healthcare team plans to stick to the early stage investing strategy the firm says has provided returns in the top quartile of life science VCs. For...
07:00 , Sep 25, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Pseudomonas Multiple virulence factor regulator (MvfR) Mouse and cell culture studies have identified benzamide-benzimidazole-based inhibitors of MvfR that could help treat Pseudomonas aeruginosa infection....
07:00 , Jul 28, 2014 |  BioCentury  |  Emerging Company Profile

Spero: Killing the quiet

Persistent infections are tough to tackle with traditional antibiotics because bacteria can enter a state of slowed metabolism and form difficult to penetrate biofilms. Spero Therapeutics LLC hopes to neutralize these bacteria and increase their...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Spero Therapeutics, Roche deal

Infectious disease play Spero granted Roche the exclusive option to acquire Spero's lead antibiotic program, a preclinical inhibitor of an undisclosed target in a quorum-sensing pathway that Spero said "controls the virulence and persistence of...
00:05 , Apr 10, 2014 |  BC Extra  |  Company News

Spero, Roche in infectious disease deal

Infectious disease play Spero Therapeutics LLC (Cambridge, Mass.) granted Roche (SIX:ROG; OCTQX:RHHBY) the exclusive option to acquire Spero's lead antibiotic program, a preclinical inhibitor of an undisclosed target in a quorum-sensing pathway that Spero said...